PMID- 22810319
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20120719
IS  - 1080-2371 (Print)
IS  - 1080-2371 (Linking)
VI  - 16
IP  - 3 Epilepsy
DP  - 2010 Jun
TI  - Antiepileptic drugs: adverse effects and drug interactions.
PG  - 136-58
LID - 10.1212/01.CON.0000368236.41986.24 [doi]
AB  - The goal of epilepsy treatment is no seizures and no side effects. Antiepileptic 
      drugs (AEDs) are the mainstay of treatment. Chronic use, however, often leads to 
      serial drug changes over time, exposing patients with epilepsy (PWE) to recurrent 
      risks due to adverse effects (AEs) and drug interactions. Both unwanted acute and 
      chronic AEs may occur that are usually dose-related, suggested by AED 
      pharmacology, and addressed with appropriate use of serum drug concentrations. 
      Idiosyncratic AEs can pose significant health issues for PWE and be lifesaving 
      with early identification. AED pharmacokinetics and pharmacodynamic properties 
      serve as the foundation for anumber of drug interactions. Hepatic enzyme systems 
      may facilitate AED interaction with other coadministered medication through 
      induction or inhibition of drug metabolism and result in AEs or seizures from 
      drug interactions. A working knowledge of AED pharmacology is an essential 
      component of good clinical practice to help clinicians predict potential AEs and 
      DIs in the treatments of PWE.
FAU - Tatum, William O
AU  - Tatum WO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Continuum (Minneap Minn)
JT  - Continuum (Minneapolis, Minn.)
JID - 9509333
EDAT- 2010/06/01 00:00
MHDA- 2010/06/01 00:01
CRDT- 2012/07/20 06:00
PHST- 2012/07/20 06:00 [entrez]
PHST- 2010/06/01 00:00 [pubmed]
PHST- 2010/06/01 00:01 [medline]
AID - 00132979-201006000-00009 [pii]
AID - 10.1212/01.CON.0000368236.41986.24 [doi]
PST - ppublish
SO  - Continuum (Minneap Minn). 2010 Jun;16(3 Epilepsy):136-58. doi: 
      10.1212/01.CON.0000368236.41986.24.